The CHOICE trial showed hearing aids didn't significantly reduce dementia conversion for older adults with MCI, despite a secondary signal of cognitive gain.
In September 2026, researchers published findings from the CHOICE trial in JAMA Neurology regarding hearing aids and older adults with mild cognitive impairment. The report, which was covered by MedPage Today, stated that hearing-aid use did not significantly reduce dementia conversion. A secondary measure did find more cognitive improvement in the intervention group compared to the control group.
Medical research frequently investigates the relationship between sensory health and cognitive decline. The CHOICE trial set out to evaluate whether treating hearing loss could specifically affect cognitive outcomes. The researchers focused their attention on older adults who already had mild cognitive impairment. Mild cognitive impairment represents a transitional stage between expected age-related changes and more serious decline.
The trial enrolled 703 adults living in Shanghai to participate in the study. All of the participants had a diagnosis of mild cognitive impairment alongside moderate-to-severe hearing loss. The participants had a mean age of 74.5 years old. Men made up 64 percent of the enrolled group.
Researchers divided these adults into two distinct groups to compare different approaches. The intervention group included 353 people who were assigned to receive hearing aids. The control group consisted of 350 people who received hearing-care education instead of physical devices. This structure allowed the scientific team to isolate the effects of the hearing aids over time.
The study team tracked these groups over a 24-month period to observe any cognitive changes. They measured the primary outcome using the Clinical Dementia Rating scale. The main goal was to measure how many patients converted from mild cognitive impairment to dementia-level impairment. The researchers wanted to see if the hearing intervention slowed this progression.
The primary outcome results did not show a major difference between the two groups. Over the 24 months, conversion to dementia occurred in 3.09 percent of the hearing-aid group. In the control group, conversion occurred in 4.74 percent of the participants. The difference between these two rates was not statistically significant.
In statistical terms, the relative risk was 0.59 with a P value of 0.23. The researchers noted that the overall rate of dementia conversion was substantially lower than they anticipated. This low conversion rate meant that the primary outcome of the trial was ultimately underpowered. The study authors interpreted this null result to mean that a benefit was not proven.
They cautioned that the data should not be read as proof of absolutely no benefit. While the primary outcome fell short, the researchers had also established a prespecified secondary outcome. This secondary measure tracked the rate of cognitive improvement among the participants. The team looked for patients who improved from a Clinical Dementia Rating score of 0.5 down to a score of 0.
A score of 0 serves as the study threshold for normal cognition. The trial data showed that 15.34 percent of the hearing-aid group reached this improved score. Only 2.36 percent of the control group achieved the same normal cognition rating. This secondary finding produced a relative risk of 5.94 and was highly significant.
For older adults managing sensory changes, these findings provide a helpful framework for medical discussions. Hao Wu, the lead author of the study, offered a balanced perspective on the results. He stated that the cognitive improvement finding is a signal that hearing intervention may help some people with mild cognitive impairment. He also noted that hearing aids offer clear communication and social engagement benefits.
These communication benefits improve the daily quality of life regardless of their effect on cognition. If hearing loss makes conversation or group activities difficult, a thorough hearing assessment is worthwhile. Improving the ability to interact with family and friends supports an active lifestyle. Adults seeking ways to build resilience in their daily routines often find that social connection relies heavily on functional hearing.
Adults who have concerns about their memory should discuss them directly with a qualified clinician. The CHOICE trial results do not replace the need for personalized medical advice. A doctor can evaluate whether an individual's mild cognitive impairment might benefit from specific interventions. The trial data confirms that patients should pursue hearing treatments primarily for their auditory and social benefits.
Readers must look at the study limitations to understand the complete picture of this research. The study authors openly acknowledged several issues with their trial design and measurement tools. The eligibility criterion based on the Clinical Dementia Rating was not prespecified in the trial registration. The research team also used a subjective rating scale for both screening and clinical outcomes.
Because of these structural limitations, Hao Wu stressed that the cognitive improvement finding remains exploratory. The lead author made it clear that this secondary result needs further confirmation in future studies. Patients should not treat hearing aids as a proven method to prevent dementia. The trial failed to establish a statistically significant reduction in conversion to severe impairment.
Other medical professionals have reviewed the CHOICE trial and offered similar words of caution. In a published commentary, Justin Golub and his co-authors discussed the large effect size for cognitive improvement. They argued that this specific result requires independent replication before it can guide clinical practice. They stressed this point specifically because the primary outcome of the trial was not significant.
Context from other major research projects helps clarify the limitations of the current study. The 2023 ACHIEVE trial investigated sensory treatments, but it involved a completely different patient population. That older study tracked cognitively intact older adults over a three-year period. The ACHIEVE researchers found no overall treatment effect on cognitive decline for the general group.
A high-risk subgroup analysis in the ACHIEVE trial did show a positive outcome. In that specific subset, the researchers noted a 48 percent relative reduction in cognitive change following hearing intervention. The CHOICE and ACHIEVE findings are not definitive proof that hearing aids prevent dementia. They examined different populations and different clinical outcomes entirely.
The intersection of sensory health and mental sharpness continues to be an active area of medical research. The latest trial offers a promising signal without delivering an absolute medical guarantee. Older adults should approach hearing devices as practical tools for maintaining independence and daily engagement. They should not view them as a primary treatment for memory loss or brain aging.
Maintaining strong communication channels helps older adults stay connected to their communities. A targeted approach to aging involves reading objective reporting on memory protection that separates true clinical findings from marketing hype. The CHOICE trial demonstrates that treating hearing loss may offer some cognitive support for certain populations. The primary clinical focus must remain on the proven social and auditory benefits of the devices.
Medical science will continue to investigate the exact mechanisms connecting the ears and the brain. Until those mechanisms are fully understood, practical symptom management remains the best path forward. Older adults can confidently address their hearing loss knowing it supports their overall well-being. They can take these steps without relying on unrealistic expectations for cognitive reversal, a cautious approach supported throughout our materials covering brain aging and performance.
Evaluating hearing treatments for cognitive protection requires accepting that these interventions do not offer guaranteed dementia prevention. A loss of structure, learning opportunities or purpose after retirement frequently leaves older adults feeling adrift when making health decisions, and FitBrainLab delivers clear research analysis to help you regain confidence in your daily planning.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
